Wavelength-Pharmaceuticals-Insert
X

Find Clinical Drug Pipeline Developments & Deals by Stemline Therapeutics

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tagraxofusp

            Therapeutic Area: Oncology Product Name: Elzonris

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Menarini

            Deal Size: $677.0 million Upfront Cash: $677.0 million

            Deal Type: Acquisition June 10, 2020

            Details:

            Acquisition establishes Menarini’s presence in the U.S. biopharmaceutical oncology market. Menarini will support further development of Stemline’s ELZONRIS and enable global expansion by leveraging its commercial infrastructure in Europe and other ex-U.S. geographies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tagraxofusp

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Menarini

            Deal Size: $677.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition May 04, 2020

            Details:

            With the support of Menarini’s infrastructure, Stemline will continue its efforts to develop new applications of ELZONRIS to meet unmet needs of patients with difficult to treat diseases and cancers.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tagraxofusp

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 13, 2020

            Details:

            A Phase 1/2 trial of ELZONRIS in combination with other agents in patients with relapsed/refractory AML, treatment-naive AML unfit for chemotherapy, and high-risk myelodysplastic syndrome (MDS) is currently enrolling patients.